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Abstract In five adult patients with intractable partial epi-
lepsy, safety and feasibility of chronic bilateral electrical
stimulation of the nucleus accumbens (NAC) were assessed,
also providing initial indications of therapeutic efficacy.
Concurrent medication remained unchanged. In this phase 1
trial, clinical outcome parameters of interest were Quality of
Life in Epilepsy questionnaire (QOLIE-31-P), Beck Depres-
sion Inventory, Mini International Neuropsychiatric Inter-
view, neuropsychological testing, and Liverpool Seizure
Severity Scale. Those data were obtained after 6 months of
NAC stimulation and compared to the equivalent assessments
made directly before implantation of electrodes. Additionally,
monthly frequencies of simple partial seizures, complex par-
tial seizures (CPS), and generalised tonic–clonic seizures
(GTCS) were assessed during 3 months before electrode
implantation and at the end of 6-month NAC stimulation.
Proportion of responders, i.e. C50 % reduction in frequency
of disabling seizures (sum of CPS and GTCS), was calcu-
lated. Main findings were unchanged psychiatric and
neuropsychological assessment and a significant decrease in
seizure severity (p = 0.043). QOLIE-31-P total score trended
towards improvement (p = 0.068). Two out of five partici-
pants were responders. The median reduction in frequency of
disabling seizures was 37.5 %. In summary, we provide initial
evidence for safety and feasibility of chronic electrical stim-
ulation of the NAC in patients with intractable partial epilepsy,
as indicated by largely unchanged neurocognitive function and
psychiatric comorbidity. Even though our data are under-
powered to reliably assess efficacy, the significant decrease in
seizure severity provides an initial indication of antiictal effi-
cacy of NAC stimulation. This calls for larger and at best
randomised trials to further elucidate efficacy of NAC stimu-
lation in patients with pharmacologically intractable epilepsy.
Keywords Deep brain stimulation  Neuropsychology 
Psychiatry  Quality of life  Seizure frequency  Seizure
severity
Introduction
In patients with intractable partial epilepsies, optimal adjust-
ment of antiepileptic drugs (AED) fails to improve seizure
frequency in at least 65 % of patients [1]. Presurgical evalu-
ation of these patients leaves a substantial proportion of an
estimated 40 % unresected [2], either due to ineligibility for
surgery or because patients decide against this non-reversible
but potentially curative procedure [3]. This difficult-to-treat
patient group needs alternative treatment options. In the last
decade, deep brain stimulation (DBS) has received increasing
interest as a therapeutic option for these patients [4, 5]. Even
though DBS is reversible and verifiably safe [6], so far this
procedure has not been broadly used for intractable epilepsy.
This may be partly due to the fact that ––in contrast to most
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resective treatment strategies––DBS is not a causative treat-
ment approach and rarely results in seizure freedom [7]. Also,
in patients treated with DBS for indications other than epi-
lepsy, cognitive [8, 9], psychiatric [8, 10, 11], or behavioural
side effects [12, 13] have been known for decades and might
overshadow a differential view on this new treatment strategy
for particular epilepsy patients.
Recently, a randomised controlled clinical trial demon-
strated efficacy of electrical stimulation of the anterior nucleus
of the thalamus (ANT) in terms of seizure frequency reduction
[14]. In particular, patients with temporal lobe epilepsy appear
to benefit from ANT stimulation [14, 15]. However, depres-
sion and memory impairments were significantly increased in
patients with ANT stimulation [14]. Another single-blind trial
evaluated the antiictal efficacy of centromedian thalamic
(CMT) nucleus DBS [16]. The authors found no relevant
effect in terms of seizure frequency reduction in patients with
frontal lobe epilepsy, whereas in patients with generalised
epilepsy, mean reduction in seizure frequency was 77 %.
Other targets, such as the Ncl. subthalamicus have been dis-
cussed as possibly effective in small uncontrolled trials [17–
19]. Recently, this target has been chosen for distinct epilepsy
syndromes, such as progressive myoclonus epilepsy [18] and
epilepsy due to ring chromosome 20 [20].
To identify and characterise new DBS targets for
patients with difficult-to-treat epilepsy, we assessed safety
and indications of chronic bilateral stimulation of the
nucleus accumbens (NAC).
This structure plays a decisive role in both functional and
anatomical connectivity between frontal and temporal lobes
[21, 22]. In rodent models of generalised [23, 24] and both
temporal [25–28] and frontal lobe seizures [29], the NAC
has been shown to be involved in propagation of epileptic
activity. Furthermore, NAC stimulation has been demon-
strated to elicit euphoria in psychiatrically unaffected
patients [30] and to ameliorate symptoms in patients with
major depression [31]. Patients with epilepsy are at high risk
for comorbid depression [32] and common network char-
acteristics for both disorders have been proposed [32, 33].
In the following, we report clinical outcome of NAC
stimulation in five patients with intractable partial epilepsy
following an in-house protocol. We assessed the effect of
electrical stimulation on quality of life, psychiatric and
neuropsychological parameters, and additionally on
severity and frequency of disabling seizures.
Methods
In-house protocol for deep brain stimulation
Five patients with medically intractable partial epilepsy
(defined as failure of at least two AEDs in adequate doses
to produce seizure freedom for at least 12 months [34])
became part of our in-house protocol for bilateral DBS of
the NAC between January 2010 and December 2012. All
patients first underwent comprehensive assessment for
potential resective epilepsy surgery. Resection or advised
invasive EEG monitoring was refused by the patients, or
resection was not advisable at all or had been ineffective.
Subsequently, patients were only offered DBS surgery if
they had an average frequency of at least one disabling
seizure per month (complex partial seizure [CPS], and/or
generalised tonic–clonic seizure [GTCS]). Patients were
not offered DBS if they suffered from progressive neuro-
degenerative disorders or had additional non-epileptic sei-
zures, if IQ was lower than 70, if they were pregnant, or if
they were currently treated with vagus nerve stimulation.
As chronic stimulation of the vagus nerve and of the
ANT has been shown to be efficacious in large-scale
controlled trials [14, 35], all patients with intractable and
non-resectable partial epilepsy were subsequently offered
these widely accepted minimally invasive surgery options
and our in-house protocol for NAC stimulation (details see
below). The five patients reported here took part in pre-
operation interviews, in which all eligible patients were
informed about different levels of evidence concerning
safety and efficacy, current legal status of approval, and the
extent of invasiveness of each surgical procedure. The
possible risk of any surgical intervention led ten eligible
patients to decide against any optional minimally invasive
procedure. Two patients opted for VNS because the sur-
gical intervention does not involve the brain, and another
two patients decided for DBS of the ANT because of the
greater evidence for efficacy. According to our pre-inter-
ventional discussions with patients, those who elected to
undergo DBS felt that the risk of invasive surgery was
outweighed by the possible benefit of direct effects on deep
brain structures, as opposed to an indirect influence via a
cranial nerve.
Outcome parameters of interest were mean change in
patient-reported outcome questionnaires including Liver-
pool Seizure Severity Scale (LSSS) [36], Beck Depression
Inventory (BDI-IA) [37], Quality of Life in Epilepsy
Questionnaire (QOLIE-31-P) [38], and a standardised
psychiatric interview employing Mini International Neu-
ropsychiatric Interview (MINI) [39], as well as a neuro-
psychological test battery. The latter covered in detail the
areas of attentional performance [test of attentional per-
formance (TAP 2.2)], cognitive speed [trail making test
(TMT), performance evaluation system subtest 7 (LPS, i.e.
Leistungspruefungssystem, subtest 7), d2–attention stress
test], executive function [‘‘Regensburger’’ word fluency
test (RWT), Hamasch 5-point test [H5PT)], memory and
learning functions [verbal learn and memory test (VLMT),
Wechsler Memory Scale-Revised (WMS-R)], and word
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retrieval (Boston naming test). All parameters were pre-
operatively assessed and compared to the results at the end
of 6-month NAC stimulation. We also assessed the pro-
portion of responders (C50 % seizure frequency reduction)
comparing the mean frequency of disabling seizures sur-
veyed in the 3 months prior to electrode implantation to the
data after 6 months of NAC stimulation. AEDs remained
unchanged 3 months before electrode implantation and
during 6 months of follow-up.
Surgery
Implantation of DBS systems was performed under general
anaesthesia. Using standardised stereotactic technique, four
Medtronic Model 3387 DBS leads (Medtronic, Minne-
apolis, MN, USA) were implanted bilaterally into the NAC
and ANT and subsequently connected to a single impulse
generator (IPG; Activa-PC, Medtronic, MA, USA). We
defined the NAC target referred to the most distal contact
of the quadripolar electrode to a point 2 mm rostral to the
anterior commissure at the level of the mid-sagittal plane,
3–4 mm ventral and 6–8 mm lateral of the midline [40]. In
addition, we modified the atlas coordinates according to the
individual treatment planning-MRI displaying on coronal
reconstructions of a 3D-MPRAGE series (3 T scanner,
0.8 mm3 resolution) the medial border (vertical limb of
Broca’s diagonal band) and the ventral border (olfactory
tubercle/horizontal limb of Broca’s diagonal band) of the
NAC region (Fig. 1). The angulation of the trajectory rel-
ative to the intercommissural line was chosen to cover with
two electrode contacts the central/lateral part (NAC core)
and the medial part (NAC shell) [40, 41]. ANT targeting
was also guided by atlas-based coordinates (Schaltenbrand
and Wahren, 6 mm lateral to, 8 mm anterior to and 12 mm
above the midcommisural point) and direct visualisation of
this nucleus on 3D-MPRAGE images [42]. The electrode
localisation was documented intraoperatively by stereo-
tactic X-ray imaging using X-ray tubes installed in the OR
and by postoperative CT examinations. CT as well as X-ray
images were fused with the planning-MRI (Fig. 1).
Following surgery, NAC stimulation was initiated after
mean 20.4 days (±10.5) and continued for 6 months
(125 Hz, 5 V, 90 ls, 1 min on, 5 min off). Voltage
reduction in 2 V steps was allowed in case of unexpected
events such as pending series of disabling seizures, status
epilepticus, or severe cognitive or psychiatric impairments.
Additional ANT electrode implantation was chosen to
allow for alternative chronic stimulation of the ANT in
case of ineffective NAC stimulation (but in all five
patients, ANT stimulation has not been used). Chronic
stimulation of the ANT has been shown to be effective
regarding frequency of CPS and severely impairing sei-
zures [14]. The Institutional Review Board of the Univer-
sity of Magdeburg approved the surgical procedure
(registration number 03/08). All patients granted written
informed consent for implantation of the neurostimulation
system.
Statistics
Due to interindividual heterogeneity, scores of neurocog-
nitive testing at the end of the NAC stimulation period
were related to values collected prior to electrode
implantation and expressed as fractions of one. After
Fig. 1 Distal electrode position
in the NAC, depicted
postoperatively with CT-fused
presurgical T1–MRI in coronal
and axial view (red circles).
Both distal contacts of the
quadripolar electrodes were
placed in the NAC as intended,
the third contact within the
transition area to the medial
border of the abutting internal
capsule and the highest, i.e. the
fourth contact at a point in the
most medial part of the capsule
or in the transition area to the
caudate. Asterisks mark the
medial and ventral border of the
NAC region. The red square
depicts an electrode lead to the
left anterior nucleus of thalamus
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testing for Gaussian distribution (Kolmogorov–Smirnov
test), which was negative for all parameters, the Wilcoxon
rank sum test was used for comparison of ordinal data.
Categorial data were tested with Fisher’s exact test. P val-
ues \0.05 (two-sided) were considered statistically
significant.
Results
Five patients (2 females), 30–53 years old (mean,
41.6 ± 10.6 years), were diagnosed with epilepsy
17–32 years (mean 23.6 ± 7.3 years) prior to DBS sur-
gery. Clinical details are summarised in Table 1. Presur-
gical video-EEG evaluation revealed seizure onset zones in
left mesio-temporal (2 patients), bilateral mesio-temporal,
left fronto-temporal or bilateral frontal (each 1 patient)
structures. Only one patient with left mesio-temporal epi-
lepsy had undergone prior resective surgery (anterior
temporal lobectomy due to hippocampal sclerosis, no sei-
zure freedom), all other patients had non-lesional 1.5 or
3.0 T MRI. At time of electrode implantation, patients
were administered 2–4 (mean 2.6) AEDs.
Regarding seizure severity, the LSSS was significantly
reduced after 6 months of NAC stimulation as compared to
scores prior to implantation of electrodes (p = 0.043).The
QOLIE-31-P total score as well as its subscales ‘‘seizure
worry’’ and ‘‘overall’’ improved only by trend (both
p = 0.068). Neuropsychological testing, the MINI and the
BDI-IA did not show significant differences after NAC
stimulation in comparison to examinations before electrode
implantation (Table 2). Two out of five patients were
responders with C50 % frequency reduction of disabling
seizures (patient #3, 50 %, and patient #4, 85.4 % reduc-
tion). Both responders’ and non-responders’ distal contacts
were inside the target zone, as postoperative CT as well as
X-ray images fused with the planning-MRI have revealed.
Overall, we found a median reduction of disabling sei-
zure frequency of 37.5 %, but no significant changes in the
mean frequencies of simple partial seizures (SPS), CPS and
GTCS (Table 2). The time course of mean frequency of
SPS, CPS and GTCS is depicted in Fig. 2.
BDI-IA and/or MINI revealed depressive symptoms in
three patients (#3, #4, #5) prior to electrode implantation.
Following NAC stimulation, depressive symptoms
resolved in one of them (patient #4). Patients #1 and #2 did
not have depressive symptoms before surgery and at the
end of NAC stimulation. With regard to other psychiatric
entities assessed by MINI, patients #3 and #5 had new
onset generalised anxiety disorder after 6-month NAC
stimulation. However, only patient #5 had an increase in
the total number of psychiatric conditions (from 0 to 2
[generalised anxiety and major depression]). In this patient,
stimulation voltage had to be reduced as a precaution from
5 to 3 V in accordance with our in-house protocol due to
abrupt increase in seizure frequency.
Discussion
In five patients with intractable partial epilepsy, clinical
consequences of 6-month NAC stimulation were compre-
hensively assessed including quality of life, and psychiatric
and neuropsychological signs or symptoms, and seizure
severity. The main finding was a lack of deterioration of
neuropsychological parameters or psychiatric conditions,
and overall reduction in subjectively perceived seizure
severity. Concerning seizure frequency, our small cohort
revealed a median frequency reduction of disabling sei-
zures of 37.5 %, two out of five patients experienced a
Table 1 Clinical data
MRI magnet resonance imaging,
SPS simple partial seizures,
CPS complex partial seizures,
GTCS generalised tonic–clonic
seizures, AEDs, antiepileptic
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seizure reduction of at least 50 %. Looking at the time
course of seizure frequency postsurgically, there was a
decrease before stimulation was initiated (Fig. 2). This is
similar to the observation by Fisher et al. [14] and Hodaie
et al. [42] after insertion of electrodes for ANT stimulation,
and has also been reported by Valentin et al. [16] after
electrode implantation into CMT. Whether this pre-stimu-
lation decrease in seizure frequency suggests a short-term
placebo effect or a microlesional effect by electrode
implantation is still a matter of discussion.
The SANTE (stimulation of the anterior nuclei of thala-
mus for epilepsy) trial, so far the only large-scale randomised
controlled DBS study in epilepsy, showed that ANT stimu-
lation results in significant seizure frequency reduction after
3 months [14]. Complementary to the 110 patients reported
in SANTE, our five patients showed significantly reduced
seizure severity after 6 months of NAC stimulation in spite
of an overall unchanged mean seizure frequency. The non-
significant decrease in frequency of GTCS and increase of
CPS might be an explanation for this significant reduction in
Table 2 Clinical outcome after
six months of NAC stimulation
SD standard deviation, n.c not
calculated, NAC nucleus
accumbens, SPS simple partial




Score, BDI-1A Beck Depression
Inventory, version IA, QOLIE-




a 3 out of 5 patients with SPS
b 3/7 CPS
c All experienced GTCS
d Due to interindividual
heterogeneity, results of
neurocognitive testing after
NAC stimulation were related to
the individual values prior to
electrode implantation and










Patients reported outcome questionnaires (mean ± SD)
LSSS 59.00 ± 3.67 49.60 ± 8.41 0.043
BDI-1A 10.80 ± 7.46 6.60 ± 6.07 0.104
QOLIE-31-P-total score 45.87 ± 09.82 50.72 ± 08.32 0.068
Subscale ‘‘energy’’ 23.75 ± 20.67 14.69 ± 03.87 0.581
Subscale ‘‘mood’’ 25.25 ± 12.02 31.90 ± 31.05 1.000
Subscale ‘‘daily
activities’’
13.60 ± 15.16 30.00 ± 31.74 0.144
Subscale ‘‘cognition’’ 16.38 ± 13.88 26.71 ± 23.14 0.465
Subscale ‘‘medication
effects’’
34.17 ± 36.27 38.17 ± 16.30 0.465
Subscale ‘‘seizure
worry’’
04.85 ± 03.52 19.30 ± 14.60 0.068
Subscale ‘‘overall’’ 20.00 ± 17.80 30.06 ± 14.27 0.068
Neuropsychiatric interview—MINI (number of participants)
Major depression 2/5 1/5 1.000
Suicidal tendency 1/5 1/5 1.000
Mania 0/5 0/5 n.c.
Panic disturbance 1/5 0/5 1.000
Agoraphobia 0/5 0/5 n.c.




Substance addiction 0/5 0/5 n.c.




Neurocognitiond 1 1.06 ± 0.18 0.225
Attentional performance 1 1.08 ± 0.18 0.465
Cognitive speed 1 0.97 ± 0.05 0.225
Executive functions 1 1.29 ± 0.47 0.255
Memory and learning
function
1 0.95 ± 0.30 0.500
Word retrieval 1 1.03 ± 0.04 0.258
Frequency of seizure types in 28-day periods (mean ± SD)
SPSa 0.27 ± 0.37 0.50 ± 0.87 0.593
CPSb 1.27 ± 1.64 2.20 ± 4.01 1.000
GTCSc 2.27 ± 3.23 1.40 ± 1.04 0.893
Disabling seizures 3.53 ± 2.79 3.60 ± 4.93 0.893
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seizure severity. The trend to less GTCS may also be
reflected by the decrease in ‘‘seizure worry’’ score in the
quality-of-life assessment. Also, the item ‘‘seizure worry’’
correlated with seizure severity, as found in other studies
[43]. Thus, we tend to interpret the non-significant trend to
reduction in ‘‘seizure severity’’ as plausible. The lack of
statistical significance with regard to improvement of this
item and the summarised quality-of-life score is likely due to
the small number of patients. Similar to our study, Valentin
et al. comprehensively assessed the effect of DBS of the
CMT nucleus in a small number of patients (n = 11; frontal
lobe and generalised epilepsies) [16]. In seven of their
patients, seizure severity score and quality of life assess-
ments were available. Compared to the results before
implantation, a significant improvement both in seizure
severity and QOLIE-32-P total score was noted after
3 months of CM stimulation. Thus, they found that quality-
of-life score improves parallel to reduction of seizure
severity score. This correlation has already been validated in
large cohorts and seems to be independent from seizure
frequency [43–45].
NAC stimulation has been shown to ameliorate symp-
toms in patients with major depression [31, 46]. Our
standardised psychiatric evaluation by MINI revealed no
significant change in our cohort. However, one patient
benefited from NAC stimulation concerning depressive
symptoms. It cannot be determined whether this observa-
tion is seizure- or target-dependent, because this patient
(#4) was a responder with an 85.4 % reduction in seizure
frequency. Worsening of cognition and depressive
symptoms as reported due to ANT stimulation in the
SANTE trial, however, are probably target-dependent.
Even though seizure frequency declined after ANT stim-
ulation, patients complained significantly more often of
depressive symptoms and memory deficits than unstimu-
lated control subjects. In one of our patients (#4), depres-
sive symptoms resolved with decreased seizure frequency,
and patient #5 experienced an increase both in seizure
frequency and in numbers of psychiatric symptoms. Both
observations may suggest a seizure-dependent effect on
psychiatric symptoms. We therefore cannot report an
independent antidepressant effect of NAC stimulation in
our cohort.
Interestingly, our overall cohort did not show changes in
neuropsychological subscores (Table 2), indicating that
NAC stimulation seems to be inert concerning cognitive
function. An open observational study on ANT stimulation,
which allowed for AED changes, reported amelioration in
verbal memory during 12 months of stimulation [47]. In
the controlled SANTE trial, however, significantly more
patients complained of memory deficits and similarly of
depressive symptoms [14]. A plausible explanation for the
observed neurocognitive side effects is the well-known
involvement of the ANT in memory processing [48, 49].
The major methodological limitation of this case series
is the small number of patients, which renders our findings
primarily anecdotal. Also, a placebo effect of high expec-
tation due to an invasive intervention cannot be excluded
due to the uncontrolled and unblinded protocol. This,
however, included a long time period of 6 months, which
Fig. 2 Time course of mean frequency of simple partial (SPS),
complex partial (CPS) and generalised tonic–clonic seizures (GTCS).
Following 3 months of seizure survey before electrode implantation
(black arrow, surgery), stimulation of the nucleus accumbens (NAC)
was started 22.4 days (±10.5) days post-surgery (red arrow, DBS
on). Frequency of all seizure types was assessed 3 and 6 months after
onset of NAC stimulation (black arrow, 6-month follow-up). After
6 months of NAC stimulation, frequency of CPS has increased,
whereas that of GTCS has decreased. DBS: deep brain stimulation
1482 J Neurol (2014) 261:1477–1484
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in our view makes a pure placebo effect rather unlikely.
Furthermore, placebo studies found that a positive response
due to elevated post-interventional expectancy is negligible
for a long-term placebo effect [50]. Lastly, due to the
unblinded in-house protocol we cannot exclude that mic-
rolesional effects of the NAC or the ancillary implanted
ANT electrodes are in part responsible for the significantly
reduced seizure severity score. However, the SANTE trial
showed normalisation of seizure frequency within
3 months in the cohort of unstimulated patients [14]. In our
cohort, there was a marked postsurgical seizure frequency
reduction before NAC stimulation onset, which was not
sustained for more than a month (Fig. 2). These two
observations suggest a subsidence of a putative microle-
sional effect at the latest within 3 months.
To reliably assess efficacy of NAC stimulation, the cohort
is underpowered compared to well-established minimally
invasive procedures such VNS and DBS for ANT. However,
initial evidence for safety and feasibility of NAC stimulation
in patients with intractable partial epilepsy is presented, and
the findings may point to some preliminary evidence for
antiictal efficacy. The lack of neurocognitive and psychiatric
side effects merits possible advantages for the target NAC, so
we conclude that further exploration of this target would be
worthwhile. To assess for placebo or microlesional effects, a
randomised controlled trial would be required. Furthermore,
a larger number of patients would be necessary to confirm
antiictal effects of NAC stimulation and to discriminate
putative responders and non-responders according to their
electroclinical features.
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